Allergy and Immunology · Houston, TX
NPI
1407349442
Since 2018
Specialty
Allergy and Immunology
Code 207K00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
6410 Fannin St Ste 720
Houston, TX, 77030
Phone (405) 889-6229
Groups this clinician bills Medicare through
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$1.1M
119 prescriptions
Company payments, 2025
$458
From 12 companies
Medicare prescription drug claims, 2024
In 2024, the drug Sarah M Nimri prescribed most often to Medicare patients was Fluticasone Propionate, with 24 prescriptions and refills. In total Sarah M Nimri wrote 119 Medicare prescriptions that cost $1.1M.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-09-23.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Fluticasone Propionate Generic | 24 | 28 | Under 11 | $293 |
| Azelastine Hcl Generic | 23 | 30 | Under 11 | $667 |
| Actimmune Interferon Gamma-1b,recomb. | 13 | 13 | Under 11 | $831K |
| Haegarda C1 Esterase Inhibitor | 12 | 12 | Under 11 | $266K |
Brand drugs: 41 claims; generic drugs: 78 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sarah M Nimri $458 ($458 in general payments such as food, travel and fees) from 12 companies. The largest payer was ARS Pharmaceuticals Operations, Inc. with $63.11.
| Company | Payments | Amount |
|---|---|---|
| ARS Pharmaceuticals Operations, Inc. SPRY | 4 | $63.11 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $60.76 |
| Novartis Pharmaceuticals Corporation NVS | 2 | $55.97 |
| Pharming Healthcare, Inc. | 2 | $53.89 |
| Grifols USA, LLC | 2 | $46.38 |
| Blueprint Medicines Corporation SNY | 1 | $34.73 |
| Regeneron Healthcare Solutions, Inc. REGN | 1 | $31.13 |
| CSL Behring CSL.AX | 1 | $30.73 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 1 | $27.66 |
| Lilly USA, LLC LLY | 1 | $24.46 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.